Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
10.97
-0.11 (-0.99%)
At close: Dec 20, 2024, 4:00 PM
11.67
+0.70 (6.38%)
After-hours: Dec 20, 2024, 4:03 PM EST
Immunome Employees
Immunome had 55 employees as of December 31, 2023. The number of employees increased by 18 or 48.65% compared to the previous year.
Employees
55
Change (1Y)
18
Growth (1Y)
48.65%
Revenue / Employee
$184,164
Profits / Employee
-$5,551,782
Market Cap
684.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | 39 | 16 | 69.57% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Avanos Medical | 3,771 |
| Bioventus | 970 |
| Relay Therapeutics | 323 |
| Evolus | 273 |
| Kura Oncology | 142 |
| Keros Therapeutics | 136 |
| Dianthus Therapeutics | 53 |
| Oculis Holding AG | 36 |
IMNM News
- 19 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 5 weeks ago - Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference - Business Wire
- 7 weeks ago - Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 - Business Wire
- 2 months ago - Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium - Business Wire
- 2 months ago - Immunome Appoints Roee Shahar as Executive Vice President, Commercial - Business Wire
- 3 months ago - Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 - Business Wire